Fmoc-L-3-吖丁啶羧酸 | 193693-64-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - FMOC-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: Fmoc-L-3-吖丁啶羧酸
• 中文别名: FMOC-3-吖丁啶羧酸；1-FMOC-AZETIDINE-3-CARBOXYLICACIDFMOC-L-3-吖丁啶羧酸；N-[(9H-芴-9-基甲氧基)羰基]-L-氮杂环丁烷-3-羧酸；1-FMOC-氮杂环丁烷-3-羧酸；1-Fmoc-3-羧基氮杂环丁烷；1-Fmoc-3-吖丁啶羧酸；Fmoc-氮杂环丁烷-3-羧酸
• 英文名称: 1-(((9H-fluoren-9-yl)methoxy)carbonyl)azetidine-3-carboxylic acid
• 英文别名: Fmoc-azetidine-3-carboxylic acid；1-Fmoc-azetidine-3-carboxylic acid；1-(9H-fluoren-9-ylmethoxycarbonyl)azetidine-3-carboxylic acid
• CAS: 193693-64-0
• 化学式: C₁₉H₁₇NO₄
• mdl: MFCD01321018
• 分子量: 323.348
• InChiKey: QDEJCUHGSHSYQH-UHFFFAOYSA-N

物化性质

• 熔点：
  174 °C
• 沸点：
  540-545℃
• 密度：
  1.368
• 闪点：
  282°(540°F)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.263
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37,S60
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 1-Fmoc-azetidine-3-carboxylic acid
CAS-No. : 193693-64-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C19H17NO4
Molecular Weight : 323,34 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

化学性质：淡黄色固体

反应信息

• 作为反应物：
  描述：

  Fmoc-L-3-吖丁啶羧酸 在 2,4,6-三甲基吡啶 、 ammonium peroxydisulfate 作用下， 以 氘代二甲亚砜 为溶剂， 反应 16.0h， 以31%的产率得到(9H-fluoren-9-yl)methyl azetidine-1-carboxylate
  参考文献：
  名称：

  脂肪族羧酸的直接加氢脱羧：无金属和无光

  摘要：

  已经开发了一种用于脂肪族羧酸直接加氢脱羧的温和且廉价的方法。该反应不需要金属、光或催化剂，使该协议操作简单、易于扩展且更具可持续性。至关重要的是，在大多数情况下不需要额外的 H 原子源，同时观察到广泛的底物范围和官能团耐受性。

  DOI：

  10.1021/acs.orglett.1c04079

文献信息

• Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
  申请人：——

  公开号：US20040186292A1

  公开（公告）日：2004-09-23

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS. The compounds of the invention for the general Formula I: 1 wherein: Z is 2 Q is selected from the group consisting of: 3 —W— is 4

  这项发明提供了具有药物和生物影响特性的化合物，它们的药物组合物和使用方法。具体来说，该发明涉及具有独特抗病毒活性的新哌啶4-烯基衍生物。更具体地，本发明涉及用于治疗HIV和艾滋病的化合物。该发明的化合物为一般式I的化合物：其中：Z是，Q是从以下组中选择的：—W—是
• Identification of Shc Src Homology 2 Domain-Binding Peptoid−Peptide Hybrids
  作者：Won Jun Choi、Sung-Eun Kim、Andrew G. Stephen、Iwona Weidlich、Alessio Giubellino、Fa Liu、Karen M. Worthy、Lakshman Bindu、Matthew J. Fivash、Marc C. Nicklaus、Donald P. Bottaro、Robert J. Fisher、Terrence R. Burke

  DOI：10.1021/jm800789h

  日期：2009.3.26

  fluorescence anisotropy (FA) competition-based Shc Src homology 2 (SH2) domain-binding was established using the high affinity fluorescein isothiocyanate (FITC) containing peptide, FITC-NH-(CH2)4-CO-pY-Q-G-L-S-amide (8; Kd = 0.35 microM). Examination of a series of open-chain bis-alkenylamide containing peptides, prepared as ring-closing metathesis precursors, showed that the highest affinities were obtained

  使用含有高亲和力异硫氰酸荧光素 (FITC) 的肽 FITC-NH-(CH2)4-CO-pY-QGLS-酰胺，建立了基于荧光各向异性 (FA) 竞争的 Shc Src 同源性 2 (SH2) 结构域结合。 8；Kd = 0.35 microM)。对一系列含开链双链烯基酰胺的肽（作为闭环复分解前体制备）的检查表明，通过用 N α 取代的 Gly (NSG)“类肽”残基替换原始 Gly 残基获得了最高的亲和力。这提供了“Ac-pY-Q-[NSG]-L-酰胺”形式的拟肽-肽杂合体。根据 NSG 取代基的不同，这些杂交中的某些表现出比含 Gly 的亲本肽 (IC50 = 248 microM) 高 40 倍的 Shc SH2 结构域结合亲和力（例如，对于 N-高烯丙基类似物 50，IC50 = 6微）。据我们所知，这项工作代表了类肽-肽杂交体在 SH2 结构域结合拮抗剂设计中应用的第一个成功例子。这些结果可为
• [EN] CELL PENETRATING PEPTIDES MODIFIED BY GLYCOSYLATION<br/>[FR] PEPTIDES DE PÉNÉTRATION CELLULAIRE MODIFIÉS PAR GLYCOSYLATION
  申请人：UNIV OXFORD INNOVATION LTD

  公开号：WO2018150196A1

  公开（公告）日：2018-08-23

  The present invention relates to peptides, in particular cell penetrating peptides, of 40 amino acid residues or less comprising at least one directly glycosylated amino acid residue and one or more arginine rich arm domains, and to conjugates of such cell penetrating peptides with a therapeutic molecule. The present invention further relates to the use of the peptides or conjugates in methods of treatment or as a medicament, especially in the treatment of genetic disorders of the central nervous system.

  本发明涉及肽，特别是40个氨基酸残基或更少的细胞穿透肽，包括至少一个直接糖基化的氨基酸残基和一个或多个富含精氨酸的臂域，并且涉及这种细胞穿透肽与治疗分子的结合物。本发明还涉及使用这些肽或结合物的治疗方法或药物，特别是用于治疗中枢神经系统的遗传性疾病。
• INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES
  申请人：Wang Tao

  公开号：US20080188481A1

  公开（公告）日：2008-08-07

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS. The compounds of the invention for the general Formula I: wherein: Z is Q is selected from the group consisting of: —W— is

  本发明提供了具有药物和生物影响性质的化合物，它们的制药组合物和使用方法。具体而言，本发明涉及具有独特的抗病毒活性的新的哌啶4-烯基衍生物。更具体地，本发明涉及用于治疗HIV和艾滋病的化合物。本发明的化合物一般公式为I：其中：Z是Q是从以下组中选择的：-W-是
• Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
  申请人：Flohr Stefanie

  公开号：US20050085483A1

  公开（公告）日：2005-04-21

  Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.

  氮取代的六氢吡嗪并[1,2-a]嘧啶-4,7-二酮衍生物及其制备方法和作为药物的用途。本发明涉及取代的六氢吡嗪并[1,2-a]嘧啶-4,7-二酮衍生物及其生理耐受盐和生理功能衍生物，其中基团具有所述含义，并描述了其生理耐受盐及其制备方法。该化合物适用于例如作为厌食剂。